Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
INSV's Cash to Debt is ranked higher than
100% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. INSV: No Debt )
INSV' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: No Debt

Equity to Asset -2.12
INSV's Equity to Asset is ranked lower than
57% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. INSV: -2.12 )
INSV' s 10-Year Equity to Asset Range
Min: -5.91   Max: 0.95
Current: -2.12

-5.91
0.95
Interest Coverage 1.66
INSV's Interest Coverage is ranked lower than
52% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.95 vs. INSV: 1.66 )
INSV' s 10-Year Interest Coverage Range
Min: 0.06   Max: 9999.99
Current: 1.66

0.06
9999.99
F-Score: 4
Z-Score: -61.58
M-Score: -22.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -74.70
INSV's Operating margin (%) is ranked higher than
51% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.59 vs. INSV: -74.70 )
INSV' s 10-Year Operating margin (%) Range
Min: -889900   Max: 42.52
Current: -74.7

-889900
42.52
Net-margin (%) 270.97
INSV's Net-margin (%) is ranked higher than
99% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.31 vs. INSV: 270.97 )
INSV' s 10-Year Net-margin (%) Range
Min: -860000   Max: 23.29
Current: 270.97

-860000
23.29
ROA (%) 233.32
INSV's ROA (%) is ranked higher than
100% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. INSV: 233.32 )
INSV' s 10-Year ROA (%) Range
Min: -441.9   Max: 63.43
Current: 233.32

-441.9
63.43
ROC (Joel Greenblatt) (%) -476.43
INSV's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.17 vs. INSV: -476.43 )
INSV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8660.97   Max: 1449.67
Current: -476.43

-8660.97
1449.67
Revenue Growth (%) 20.90
INSV's Revenue Growth (%) is ranked higher than
87% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. INSV: 20.90 )
INSV' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 188.4
Current: 20.9

0
188.4
EBITDA Growth (%) 115.40
INSV's EBITDA Growth (%) is ranked higher than
99% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. INSV: 115.40 )
INSV' s 10-Year EBITDA Growth (%) Range
Min: -45   Max: 115.4
Current: 115.4

-45
115.4
» INSV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with INSV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 1.20
INSV's P/E(ttm) is ranked higher than
99% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.00 vs. INSV: 1.20 )
INSV' s 10-Year P/E(ttm) Range
Min: 0.62   Max: 41.33
Current: 1.2

0.62
41.33
P/S 3.10
INSV's P/S is ranked lower than
53% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. INSV: 3.10 )
INSV' s 10-Year P/S Range
Min: 0.55   Max: 269
Current: 3.1

0.55
269
EV-to-EBIT -4.21
INSV's EV-to-EBIT is ranked lower than
56% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. INSV: -4.21 )
INSV' s 10-Year EV-to-EBIT Range
Min: -237.7   Max: 183.1
Current: -4.21

-237.7
183.1
Current Ratio 0.14
INSV's Current Ratio is ranked lower than
57% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. INSV: 0.14 )
INSV' s 10-Year Current Ratio Range
Min: 0.06   Max: 16.2
Current: 0.14

0.06
16.2
Quick Ratio 0.14
INSV's Quick Ratio is ranked lower than
57% of the 890 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. INSV: 0.14 )
INSV' s 10-Year Quick Ratio Range
Min: 0.05   Max: 16.2
Current: 0.14

0.05
16.2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.80
INSV's Price/Median PS Value is ranked lower than
54% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. INSV: 0.80 )
INSV' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 52.27
Current: 0.8

0.21
52.27
Earnings Yield (Greenblatt) -23.80
INSV's Earnings Yield (Greenblatt) is ranked lower than
51% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. INSV: -23.80 )
INSV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -23.8   Max: 38.9
Current: -23.8

-23.8
38.9
Forward Rate of Return (Yacktman) -15.91
INSV's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. INSV: -15.91 )
INSV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -109.3   Max: 14.6
Current: -15.91

-109.3
14.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
InSite Vision Inc was incorporated in 1986 as a California Corporation and reincorporated in Delaware in 1987. The Company is an ophthalmic product development company committed to advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company completed its initial public offering on October 18, 1993. The Company's current portfolio of ophthalmic pharmaceutical products is based on its proprietary DuraSite drug delivery technology. The Company's DuraSite sustained drug delivery technology is a proven, patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and could be customized for delivering a variety of potential drug candidates. The Company has focused its research, development and commercial support efforts on the following topical products formulated with its DuraSite drug delivery technology. AzaSite or azithromycin ophthalmic solution 1% is a DuraSite formulation of azithromycin developed as a broad spectrum ocular antibiotic and approved by the U.S. Food and Drug Administration in April 2007 to treat bacterial conjunctivitis. Additional indications are being pursued by Inspire Pharmaceuticals for this product. AzaSite was commercially launched in the United States by Inspire Pharmaceuticals in August 2007. DexaSite is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. In November 2011, it initiated a Phase 3 clinical trial for this product candidate in blepharitis and completed patient enrollment in the clinical trial in September 2012. BromSite is a DuraSite formulation of bromfenac in development for the prevention of post-operative inflammation and eye pain. It initiated a Phase 1/2 clinical trial for this product candidate in August 2010 and received positive top-line results from this study in the first quarter of 2011, which demonstrated the efficacy and safety of BromSite. DuraSite 2 is a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing superior ophthalmic therapeutics. DuraSite 2 is based on the original DuraSite technology, and incorporates a cationic polymer to achieve sustained and enhanced ocular delivery of drugs. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease. The Company is subject to regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INSV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
INSITE VISION INC Financials Nov 19 2014
10-Q for InSite Vision, Inc. Nov 09 2014
INSITE VISION INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
InSite Vision Reports Third Quarter 2014 Financial Results Nov 05 2014
INSITE VISION INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 05 2014
InSite Vision Inc Earnings Call scheduled for 4:30 pm ET today Nov 05 2014
InSite Vision Reports Third Quarter 2014 Financial Results Nov 05 2014
Q3 2014 InSite Vision Inc Earnings Release - Time Not Supplied Nov 05 2014
InSite Vision to Report Third Quarter 2014 Financial Results on November 5, 2014 Oct 29 2014
InSite Vision to Report Third Quarter 2014 Financial Results on November 5, 2014 Oct 29 2014
INSITE VISION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Oct 16 2014
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% Oct 06 2014
Weakness Seen in Vital Therapies (VTL): Stock Falls 6.3% Oct 06 2014
INSITE VISION INC Files SEC form 10-Q, Quarterly Report Aug 14 2014
InSite Vision Inc Earnings Call scheduled for 4:30 pm ET today Aug 13 2014
INSITE VISION INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 13 2014
InSite Vision Reports Second Quarter 2014 Financial Results Aug 13 2014
InSite Vision to Report Second Quarter 2014 Financial Results on August 13, 2014 Aug 05 2014
INSITE VISION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 31 2014
INSITE VISION INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK